Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

导出 OA

翻译打印收藏纠错

作者： Kayvon,Modjarrad ^[1] ; Christine C,Roberts ^[2] ; Kristin T,Mills ^[3] ; Amy R,Castellano ^[4] ; Kristopher,Paolino ^[1] ; Kar,Muthumani ^[5] ; Emma L,Reuschel ^[5] ; Merlin L,Robb ^[4] ; Trina,Racine ^[6] ; Myoung-Don,Oh ^[7] ; Claude,Lamarre ^[6] ; Faraz I,Zaidi ^[5] ; Jean,Boyer ^[8] ; Sagar B,Kudchodkar ^[9] ; Moonsup,Jeong ^[9] ; Janice M,Darden ^[4] ; Young K,Park ^[9] ; Paul T,Scott ^[1] ; Celine,Remigio ^[9] ; Ajay P,Parikh ^[4] ; Megan C,Wise ^[8] ; Ami,Patel ^[5] ; Elizabeth K,Duperret ^[5] ; Kevin Y,Kim ^[5] ; Hyeree,Choi ^[5] ; Scott,White ^[8] ; Mark,Bagarazzi ^[8] ; Jeanine M,May ^[10] ; Deborah,Kane ^[9] ; Hyojin,Lee ^[9] ; Gary,Kobinger ^[6] ; Nelson L,Michael ^[1] ; David B,Weiner ^[5] ; Stephen J,Thomas ^[1] ; Joel N,Maslow ^[9]

作者单位： Walter Reed Army Institute for Research, Silver Spring, MD, USA. ^[1] GeneOne Life Science, Seoul, South Korea. Electronic address: croberts@geneonels-us.com. ^[2] ICON Clinical Research Management, Gaithersburg, MD, USA. ^[3] Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. ^[4] Wistar Institute, Philadelphia, PA, USA. ^[5] Université Laval, Quebec City, QC, Canada. ^[6] Seoul National University College of Medicine, Seoul, South Korea. ^[7] Inovio Pharmaceuticals, Plymouth Meeting, PA, USA. ^[8] GeneOne Life Science, Seoul, South Korea. ^[9] Emmes Corporation, Rockville, MD, USA. ^[10]